Published in Infect Immun on March 01, 2001
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Capsular Material of Cryptococcus neoformans: Virulence and Much More. Mycopathologia (2012) 0.90
Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells. Immunology (2002) 0.81
Immunoregulation in Fungal Diseases. Microorganisms (2016) 0.75
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
CD28/B7 system of T cell costimulation. Annu Rev Immunol (1996) 10.48
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med (1991) 8.78
CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (1992) 7.15
B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell (1995) 6.88
Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature (1997) 5.80
CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci U S A (1989) 5.07
CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med (1996) 4.97
Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol (1994) 4.22
Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun (2000) 3.42
Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A. Mol Immunol (1980) 2.98
Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide. Infect Immun (1977) 2.84
Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun (1998) 2.60
Co-stimulation in T cell responses. Curr Opin Immunol (1997) 2.35
Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect Immun (1995) 1.86
The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev (1996) 1.76
The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev (1998) 1.68
Binding of cryptococcal polysaccharide to Cryptococcus neoformans. Infect Immun (1984) 1.52
CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol (1998) 1.45
Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. J Clin Invest (1997) 1.43
Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J Immunol (1998) 1.38
Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol (1994) 1.37
T-cell stimulation: an abundance of B7s. Nat Med (1999) 1.32
Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J Exp Med (1998) 1.32
Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans. Infect Immun (1993) 1.15
CTLA-4 and T cell activation. Curr Opin Immunol (1999) 1.13
Crossregulation between Th1 and Th2 cells. Crit Rev Immunol (1998) 1.06
Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity. Res Immunol (1998) 1.05
Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes. Eur J Immunol (1998) 1.01
Negative regulation of T cell activation. Curr Opin Immunol (1998) 0.93
Direct antimicrobial activity of T cells. Immunol Today (1995) 0.92
CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response. Infect Immun (2000) 0.89
T lymphocyte and monocyte interaction by CD40/CD40 ligand facilitates a lymphoproliferative response and killing of Cryptococcus neoformans in vitro. Eur J Immunol (2000) 0.88
B7 costimulatory ligand regulates development of the T-cell response to Cryptococcus neoformans. Immunology (1999) 0.83
The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection. Curr Opin Immunol (1999) 0.79
HIV type 1 envelope glycoprotein gp120 induces development of a T helper type 2 response to Cryptococcus neoformans. AIDS (1999) 0.79
Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol (1990) 4.37
Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. Infect Immun (1991) 2.46
Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med (1996) 2.41
Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. J Exp Med (1992) 2.37
CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. J Immunol (1993) 2.30
Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur J Immunol (1993) 2.05
Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun (1986) 1.86
An immunoregulatory role for neutrophils in CD4+ T helper subset selection in mice with candidiasis. J Immunol (1997) 1.76
IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol (2010) 1.76
IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J Immunol (1994) 1.75
Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J Immunol (1994) 1.72
Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun (1996) 1.71
A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice. Infect Immun (1994) 1.68
Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol (1997) 1.68
Interleukin-12 in infectious diseases. Clin Microbiol Rev (1997) 1.63
Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun (1997) 1.61
Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice. Infect Immun (1989) 1.56
Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun (1996) 1.53
Rapid methods to extract DNA and RNA from Cryptococcus neoformans. FEMS Yeast Res (2001) 1.52
Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species. J Clin Microbiol (2002) 1.51
Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans infection. Am J Respir Cell Mol Biol (1994) 1.51
In vitro production of tumor necrosis factor by murine splenic macrophages stimulated with mannoprotein constituents of Candida albicans cell wall. Cell Immunol (1991) 1.49
T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol (2000) 1.48
The A-domain and the thrombospondin-related motif of Plasmodium falciparum TRAP are implicated in the invasion process of mosquito salivary glands. EMBO J (1999) 1.47
Correlation between in vivo and in vitro studies of modulation of resistance to experimental Candida albicans infection by cyclophosphamide in mice. Infect Immun (1983) 1.43
T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. J Infect Dis (1995) 1.41
Interleukin 18 restores defective Th1 immunity to Candida albicans in caspase 1-deficient mice. Infect Immun (2000) 1.39
Cell wall components of Candida albicans as immunomodulators: induction of natural killer and macrophage-mediated peritoneal cell cytotoxicity in mice by mannoprotein and glucan fractions. J Gen Microbiol (1988) 1.38
Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol (1994) 1.37
Two conserved amino acid motifs mediate protein targeting to the micronemes of the apicomplexan parasite Toxoplasma gondii. Mol Cell Biol (2000) 1.36
Interleukin-12 but not interferon-gamma production correlates with induction of T helper type-1 phenotype in murine candidiasis. Eur J Immunol (1994) 1.33
In vitro natural cell-mediated cytotoxicity against Candida albicans: macrophage precursors as effector cells. J Immunol (1985) 1.30
T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice. J Immunol (1990) 1.29
Role of nitric oxide and melanogenesis in the accomplishment of anticryptococcal activity by the BV-2 microglial cell line. J Neuroimmunol (1995) 1.28
S100B expression in and effects on microglia. Glia (2001) 1.28
Interleukin-4 and -10 exacerbate candidiasis in mice. Eur J Immunol (1995) 1.27
Serodiagnosis of infectious diseases with antigen microarrays. J Appl Microbiol (2004) 1.25
Immunosuppressive effect of cyclosporin A on resistance to systemic infection with Candida albicans. J Med Microbiol (1989) 1.25
Protective immunity induced by low-virulence Candida albicans: cytokine production in the development of the anti-infectious state. Cell Immunol (1989) 1.21
Natural cell-mediated cytotoxicity against Candida albicans induced by cyclophosphamide: nature of the in vitro cytotoxic effector. Infect Immun (1983) 1.20
A comparison of experimental pathogenicity of Candida species in cyclophosphamide-immunodepressed mice. Sabouraudia (1984) 1.19
Gamma interferon modifies CD4+ subset expression in murine candidiasis. Infect Immun (1992) 1.19
Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis (1999) 1.19
Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis (1997) 1.19
Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J Infect Dis (1994) 1.19
Immunomodulation by a low-virulence, agerminative variant of Candida albicans. Further evidence for macrophage activation as one of the effector mechanisms of nonspecific anti-infectious protection. J Med Vet Mycol (1988) 1.18
CD4+ T-helper-cell responses in mice with low-level Candida albicans infection. Infect Immun (1996) 1.18
Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. Antimicrob Agents Chemother (1985) 1.18
Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect Immun (1998) 1.16
Increase of mouse resistance to Candida albicans infection by thymosin alpha 1. Infect Immun (1982) 1.13
A TH1-TH2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol (1995) 1.12
Augmentation of GG2EE macrophage cell line-mediated anti-Candida activity by gamma interferon, tumor necrosis factor, and interleukin-1. Infect Immun (1990) 1.10
[Use of potassium chloride hypertonic saline solution (3M KC1) for extraction of soluble antigens from Candida albicans]. Ann Sclavo (1976) 1.10
Experimental model of intracerebral infection with Cryptococcus neoformans: roles of phagocytes and opsonization. Infect Immun (1992) 1.10
In-vitro killing of Candida species by murine immunoeffectors and its relationship to the experimental pathogenicity. Sabouraudia (1985) 1.09
Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans. Infect Immun (2001) 1.08
Azole derivatives of 1,4-benzothiazine as antifungal agents. Bioorg Med Chem (1998) 1.08
Course of primary candidiasis in T cell-depleted mice infected with attenuated variant cells. J Infect Dis (1992) 1.07
Defective co-stimulation and impaired Th1 development in tumor necrosis factor/lymphotoxin-alpha double-deficient mice infected with Candida albicans. Int Immunol (1998) 1.07
Intracerebral transfer of an in vitro established microglial cell line: local induction of a protective state against lethal challenge with Candida albicans. J Neuroimmunol (1991) 1.07
Early induction of interleukin-12 by human monocytes exposed to Cryptococcus neoformans mannoproteins. Infect Immun (2000) 1.06
The contribution of PARs to inflammation and immunity to fungi. Mucosal Immunol (2008) 1.06
Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pulmonary aspergillosis. J Infect Dis (2001) 1.06
Severity of group B streptococcal arthritis is correlated with beta-hemolysin expression. J Infect Dis (2000) 1.05
Inhibition of candidacidal activity of polymorphonuclear cells by alveolar macrophage-derived factor from lung cancer patients. Am Rev Respir Dis (1993) 1.05
Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? Med Mycol (1998) 1.04
Phagocytic killing of Candida albicans by different murine effector cells. Sabouraudia (1983) 1.04
Biological role of Th cell subsets in candidiasis. Chem Immunol (1996) 1.04
Differential host susceptibility to intracerebral infections with Candida albicans and Cryptococcus neoformans. Infect Immun (1993) 1.03
Intranasally delivered siRNA targeting PI3K/Akt/mTOR inflammatory pathways protects from aspergillosis. Mucosal Immunol (2009) 1.03
Immunomodulation by Candida albicans: crucial role of organ colonization and chronic infection with an attenuated agerminative strain of C. albicans for establishment of anti-infectious protection. J Gen Microbiol (1988) 1.03
TGF-beta is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans. J Immunol (1995) 1.03
Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis. Infect Immun (1999) 1.02
Modulation of anti-Candida activity of human alveolar macrophages by interferon-gamma or interleukin-1-alpha. Am J Respir Cell Mol Biol (1989) 1.01
Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis. Antimicrob Agents Chemother (1997) 1.01
Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis (1995) 0.99
Evidence of microevolution in a clinical case of recurrent Cryptococcus neoformans meningoencephalitis. Eur J Clin Microbiol Infect Dis (2001) 0.99
Macrophage colony-stimulating factor in murine candidiasis: serum and tissue levels during infection and protective effect of exogenous administration. Infect Immun (1991) 0.99
Interdependency of interleukin-10 and interleukin-12 in regulation of T-cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans. Infect Immun (2001) 0.98
Candida albicans-specific Ly-2+ lymphocytes with cytolytic activity. Eur J Immunol (1991) 0.98
A radiolabel release microassay for phagocytic killing of Candida albicans. J Immunol Methods (1982) 0.98
Specific activated T cells regulate IL-12 production by human monocytes stimulated with Cryptococcus neoformans. J Immunol (1999) 0.98